China’s top market regulator has given the green light to private equity giants Blackstone and TPG to proceed with their acquisition of US-based medical diagnostics firm Hologic, according to a regulatory approvals list published on Tuesday.
The State Administration for Market Regulation (SAMR) confirmed the deal’s clearance as part of its routine disclosure of transactions that have passed antitrust review.
Hologic specialises in medical imaging and diagnostic products, particularly in the women’s health segment, and has built a footprint in the Chinese market through production sites and collaborative arrangements.
Blackstone and TPG originally announced their plan to take Hologic private in October 2025, offering a total consideration of $18.3 billion including debt in what has been described as the largest medical devices sector acquisition in nearly two decades.
The transaction still awaits final closing conditions, including approvals from Hologic shareholders and customary regulatory clearances in other jurisdictions.
Also Read